Also found in: Dictionary, Encyclopedia.
Related to Platinol: cisplatin


trademark for a preparation of cisplatin, an antineoplastic agent.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


(plăt′ə-nôl′, -nŏl′)
A trademark for the drug cisplatin.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


A chemotherapeutic that forms covalent bonds and crosslinks with DNA, which is used for head and neck, ovarian, testicular, and bladder cancers and lymphomas.

Adverse effects
Nephrotoxicity, nausea, sensory neuropathy.

Management for adverse effects
• Nephrotoxicity: adequate hydration to maintain renal flow and high chloride concentration.
• Nausea: ondansetron, a selective antagonist of serotonin S3 receptors.
• Neuropathy: amifostine, growth factors, glutathione, Org 2766, acetyl-L-carnitine, vitamin E have all been tried; per Cochrane review, none proved effective; more studies are needed.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
because it made a less toxic alternative to Platinol available sooner to
availability of Platinol meant that FDA expected overall survival data
* For HL60, cell inhibitory rate of positive control (platinol) was 83% at [mu]g/ml.
Combinations currently in use generally include two or more of the following drugs: cisplatin (Platinol), cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), and hexamethylmelamine.
One drug combination that has been studied is CAP, which includes cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), and cisplatin (Platinol).
In 2014, the drug bevacizumab (Avastin) was approved for treating recurrent cervical cancer and ovarian cancer that are resistant to platinum-based anticancer agents, such as cisplatin (Paraplatin) and carboplatin (Platinol).
TPMT ** Tabloid, [30] thioguanine (GlaxoSmithKine) DPD ** Xeloda, [31] capecitabine (Hoffman La Roche Inc.) ER-PGR ** Aromasin, [32] exemestane (Pfizer) G6PD ** Elitek, [33] rasburicase (Sanofi- synthelabo Inc.) ER * Nolvadex, [34] tamoxifen (AstraZeneca) ER * Arimidex, [35] anastrozole (AstraZeneca) ER ** Faslodex, [36] fulvestrant (AstraZeneca) UGT1A1 ** Camptosar, [37] irinotecan (Pfizer) ERCC1 * Camptosar, [38] irinotecan (Pfizer) tpmt * Platinol, [39] cisplatin, (Bristol-Myers Squibb Company) tpmt ** Tabloid, [40] thioguanine (GlaxoSmithKline) CDK 4 and 6 * Palbociclib, PD- [41] 0332991 (Pfizer) * This biomarkers are used for diagnostic and prognostic purposes to determine the proper cause of treatment (investigational diagnostics and/or drugs).
In 2000, the American Society of Clinical Oncology (ASCO) released treatment guidelines for non-small cell lung cancer that recommend that at least one of the drugs be either carboplatin (Paraplatin) or cisplatin (Platinol).
Pemetrexed can already be used off label for any lung cancer, because it was approved in February for use in combination with cisplatin (Platinol) for mesothelioma.